A flurry of research is identifying patterns that set apart COVID-19 patients who are prone to deadly immune system overreactions. During these “cytokine storms,” molecules leading the first line of immune defense fail to stand down so that antibodies and T cells can take…

While the world awaits a vaccine, drugmakers—and the US government—are throwing resources behind a potential stop-gap solution: custom antibodies designed to fight COVID-19.   Grown in bioreactor vats, these monoclonal antibodies are copies of naturally occurring proteins…

Some people who have not been exposed to SARS-CoV-2 may still have some immunity to it—and not because they have antibodies.  

In an effort to monitor antibiotic use and improve stewardship, WHO created the AWaRe tool in 2017 that divides the drugs into 3 categories: Access, Watch, and Reserve, 

Emerging COVID-19 research is yielding differing takes on antibodies and immunity.

It’s still early days for 2 coronavirus vaccine candidates, but trial results published yesterday in The Lancet earned promising (though qualified) results.

COVID-19 may have infected ~20 million Americans—10X the official case count, the CDC said yesterday, CNN reports, citing comments from CDC chief Robert Redfield yesterday. Redfield’s estimate, based on serology testing for antibodies to the virus,…

This pandemic has made it clear that disease surveillance is too slow.   Instead of relying on a patchwork of health providers to report unusual events, what if anywhere that collects blood could be on the lookout for unusual antibodies?   That’s the aim of the Global…

Early results from human testing of a vaccine against the novel coronavirus suggest—but don’t prove—that it offers some immunity, The Washington Post reports.